ClinicalTrials.gg
TerminatedNCT02808429Updated Feb 25, 2021Results posted

Efficacy and Safety of Atacicept in IgA Nephropathy

A Phase 2 interventional study of Placebo and Atacicept 25 mg in IgA Nephropathy, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-25.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
60th of 69
16 · median 72
Started
2017
with 1 other
Phase 2
30 of 75
11 open now
Registered
16th of 75
by date

Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 60th largest by enrollment of the 69 interventional ones that give a count, is one of 2 that started in 2017, is one of 30 in phase 2, and was the 16th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.

03

Conditions studied

  • IgA Nephropathy

Keywords

  • Atacicept
  • IgA Nephropathy
  • Berger´s disease
  • Glomerulonephritis
  • Proteinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than or equal to (>=)18 years of age
  • -proven Immunoglobulin (IgA) nephropathy
  • Urine Protein to Creatinine Ratio (UPCR) >= 0.75 and \<= 6 milligram per milligram (mg/mg) during screening
  • Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Concomitant significant renal disease other than IgA nephropathy
  • IgA nephropathy with significant glomerulosclerosis or cortical scarring
  • Diagnosis of Henoch-Schonlein purpura
  • Failure to meet estimated (eGFR) and requirement criteria
  • Serum IgG below 6 grams per liter (g/L)
  • Use of cyclophosphamide ever or use of other or systemic within 4 months
  • Active infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks
  • History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB infection
  • History of or positive and/or positive for or at screening
  • History of
  • Nursing or pregnancy
  • Any condition, including any uncontrolled disease state other than IgA nephropathy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Placebo

    Drug: Placebo

  • Experimental
    Atacicept 25 mg

    Drug: Atacicept 25 mg

  • Experimental
    Atacicept 75 mg

    Drug: Atacicept 75 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

    Adverse Event (AE): any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: AEs that developed or worsened/became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 96\]). TEAEs included serious AEs and non- serous AEs. AESIs included infections, cardiac failure, cardiomyopathy/ ischemic heart disease, hypersensitivity reaction (including anaphylactic/anaphylactoid shock conditions, asthma/bronchospasm, and angioedema), injection site reactions (ISRs) and demyelinating disorders. Investigator or his /her designee assessed ISRs as local reactions (redness, bruising, swelling, induration and itching).

    Time frame: Baseline up to 96 weeks

Secondary outcomes

  1. Serum Atacicept Concentrations

    Serum Atacicept Concentrations was to be performed; however; as per changed in planned analysis the outcome measure related to pharmacokinetic parameters was not assessed.

    Time frame: Week 0 Day 1 (pre-dose), Weeks 1, 2, 4, 8, 12, 16, 24, 40, 48, 72, Early Termination (up to Week 72) and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24

  2. Change From Baseline Levels in Serum Immunoglobulin A (IgA)

    The change in serum levels of IgA from baseline was reported.

    Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24

  3. Change From Baseline Levels in Serum Iimmunoglobulin G (IgG)

    The change in serum levels of IgG from baseline was reported.

    Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24

  4. Change From Baseline Levels in Serum Immunoglobulin M (IgM)

    The change in serum levels of IgM from baseline was reported.

    Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and at PT FU Weeks 4, 12 and 24

  5. Change From Baseline in Serum Galactose Deficient-IgA1 (Gd-IgA1) Levels

    The change in serum Gd-IgA1 from baseline was reported.

    Time frame: Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72 and at PT FU Weeks 12 and 24

  6. Change From Baseline in Serum Complement C3 and C4 Levels

    The change in serum component C3 and C4 from baseline were reported.

    Time frame: Baseline, Week 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Weeks 12 and 24

  7. Change From Baseline in Immune Cell Subsets by Flow Cytometry Analysis

    Change from baseline in immune cell subsets included total T cells, helper T cells, cytotoxic T cells, total B cells (assay with \[AW\] CD45 or assay without \[AWO\] CD45), mature naïve B cells, memory B cells, plasma cells, plasma blasts, and natural killer (NK) cells and were reported. Analysis was performed by flow cytometry analysis.

    Time frame: Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Week 24

  8. Change From Baseline in Urinary IgG, IgA, and IgM Levels

    Urinary IgG, IgA and IgM levels to be measured by Immuno-Electrophoresis.

    Time frame: Baseline (Day1), Weeks 24, 48 and Early Termination (up to earlier than Week 72)

  9. Percentage of Participants With Positive Anti-Drug Antibody (ADA)

    Percentage of participants with positive ADA were reported.

    Time frame: Baseline up to safety follow-up (96 weeks)

  10. Percentage of Participants With Clinical Significant Abnormalities in Laboratory Assessments

    Laboratory investigation included hematology, biochemistry, urinalysis and Urine sediment analysis. Clinical significance was to be decided by the investigator.

    Time frame: Baseline up to safety follow-up (96 weeks)

  11. Percentage of Participants With Clinical Significant Abnormalities in Vital Signs

    Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, weight and height. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was to be decided by the investigator.

    Time frame: Baseline up to safety follow-up (96 weeks)

  12. Percentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs)

    12-lead ECG were recorded after the participants have rested for at least 15 minutes in supine position. Clinically significance was decided by the investigator. The number of participants with clinically significant abnormalities in 12-lead ECG were reported.

    Time frame: Baseline up to safety follow-up (96 weeks)

07

Results

Posted Feb 25, 2021
Limitations and caveats
The study was prematurely terminated due to poor enrollment and Part B was not conducted as per Sponsor decision. This decision was not related to any safety or efficacy findings regarding Atacicept.

Participant flow

Participant flow — Overall Study
MilestonePlaceboAtacicept 25 mgAtacicept 75 mg
Started565
Completed253
Not completed312
Withdrew: Lost to follow-up100
Withdrew: Protocol violation010
Withdrew: Premature study termination by sponsor201
Withdrew: Relocation001

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

Adverse Event (AE): any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: AEs that developed or worsened/became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 96\]). TEAEs included serious AEs and non- serous AEs. AESIs included infections, cardiac failure, cardiomyopathy/ ischemic heart disease, hypersensitivity reaction (including anaphylactic/anaphylactoid shock conditions, asthma/bronchospasm, and angioedema), injection site reactions (ISRs) and demyelinating disorders. Investigator or his /her designee assessed ISRs as local reactions (redness, bruising, swelling, induration and itching).

Time frame:
Baseline up to 96 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mg
Participants with TEAE10010060
Participants with AESI: Cardiac failure000
Participants with AESI: Ischaemic heart disease000
Participants with AESI: Cardiac arrhythmia000
Partcipants with AESI: Hypersensitivity reactions2066.6720
Partcipants with AESI: Demyalinating disorders000
Partcipants with AESI: Injection site reactions083.360
Partcipants with AESI: Infections4083.3320
Participants with serious TEAEs20500
Participants with TEAEs leading to discontinuation016.660
Participants with TEAEs leading to death000
SecondarySerum Atacicept Concentrations

Serum Atacicept Concentrations was to be performed; however; as per changed in planned analysis the outcome measure related to pharmacokinetic parameters was not assessed.

Time frame:
Week 0 Day 1 (pre-dose), Weeks 1, 2, 4, 8, 12, 16, 24, 40, 48, 72, Early Termination (up to Week 72) and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24

No measurements were reported for this outcome.

SecondaryChange From Baseline Levels in Serum Immunoglobulin A (IgA)

The change in serum levels of IgA from baseline was reported.

Time frame:
Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24
Reported as:
Mean · gram per liter
Change From Baseline Levels in Serum Immunoglobulin A (IgA)
gram per literPlaceboAtacicept 25 mgAtacicept 75 mg
Change at Week 1-0.194 ± 0.3012-0.203 ± 0.1325-0.278 ± 0.1561
Change at Week 2-0.114 ± 0.2825-0.280 ± 0.1108-0.486 ± 0.2289
Change at Week 4-0.014 ± 0.3570-0.197 ± 0.1952-0.828 ± 0.2319
Change at Week 80.008 ± 0.5340-0.572 ± 0.2838-1.144 ± 0.4997
Change at Week 12-0.030 ± 0.4011-0.476 ± 0.3879-1.146 ± 0.4226
Change at Week 160.044 ± 0.4869-0.692 ± 0.3608-1.296 ± 0.4237
Change at Week 200.218 ± 0.6157-0.616 ± 0.2880-1.430 ± 0.4635
Change at Week 240.212 ± 0.3140-0.514 ± 0.4552-1.424 ± 0.5226
Change at Week 320.180 ± 0.4924-0.920 ± 0.2950-1.468 ± 0.3851
Change at Week 400.112 ± 0.7745-0.963 ± 0.2815-1.388 ± 0.3212
Change at Week 480.526 ± 1.2935-0.710 ± 0.3804-1.375 ± 0.4680
Change at Week 600.233 ± 0.3676-0.733 ± 0.3057-1.283 ± 0.4308
Change at Week 720.307 ± 0.3650-0.957 ± 0.2157-1.240 ± 0.4491
Change at Early termination0.420 ± 0.0849-0.493 ± 0.2173-1.835 ± 0.1344
Change at PT FU Week 40.300 ± 0.4757-0.452 ± 0.3529-1.223 ± 0.2515
Change at PT FU Week 120.622 ± 0.7436-0.440 ± 0.6335-0.668 ± 0.2843
Change at PT FU Week 240.563 ± 0.6716-0.420 ± 0.6503-0.370 ± 0.1160
SecondaryChange From Baseline Levels in Serum Iimmunoglobulin G (IgG)

The change in serum levels of IgG from baseline was reported.

Time frame:
Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24
Reported as:
Mean · gram per liter
Change From Baseline Levels in Serum Iimmunoglobulin G (IgG)
gram per literPlaceboAtacicept 25 mgAtacicept 75 mg
Change at Week 1-0.630 ± 0.5524-0.480 ± 0.4289-0.444 ± 0.4372
Change at Week 2-0.362 ± 0.7146-0.650 ± 0.5764-0.898 ± 0.5507
Change at Week 4-0.354 ± 0.7073-0.415 ± 0.4965-1.792 ± 0.8182
Change at Week 8-0.562 ± 1.0023-1.128 ± 0.3574-2.812 ± 1.2085
Change at Week 12-0.472 ± 0.9304-0.930 ± 0.7748-3.126 ± 0.9324
Change at Week 16-0.608 ± 1.1858-1.480 ± 0.4687-3.360 ± 0.8546
Change at Week 200.016 ± 1.0781-1.024 ± 0.3893-3.684 ± 0.7597
Change at Week 24-0.748 ± 1.0059-0.926 ± 0.8289-3.776 ± 1.0876
Change at Week 32-0.296 ± 1.1195-1.055 ± 0.5701-3.962 ± 0.8830
Change at Week 400.218 ± 0.8904-1.363 ± 0.4895-3.623 ± 0.2993
Change at Week 480.256 ± 1.5731-0.600 ± 0.7654-3.745 ± 0.4608
Change at Week 600.305 ± 1.2881-0.743 ± 1.5627-3.368 ± 0.5721
Change at Week 72-0.203 ± 1.3606-0.867 ± 0.7772-3.477 ± 0.8618
Change at Early Termination0.655 ± 0.5445-1.547 ± 0.5353-3.995 ± 0.0636
Change at PT FU Week 40.360 ± 1.7711-0.736 ± 0.7900-2.553 ± 0.7160
Change at PT FU Week 120.922 ± 1.2793-0.800 ± 1.4692-1.300 ± 0.5610
Change at PT FU Week 240.273 ± 0.9758-0.878 ± 1.03950.020 ± 1.2498
SecondaryChange From Baseline Levels in Serum Immunoglobulin M (IgM)

The change in serum levels of IgM from baseline was reported.

Time frame:
Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and at PT FU Weeks 4, 12 and 24
Reported as:
Mean · gram per liter
Change From Baseline Levels in Serum Immunoglobulin M (IgM)
gram per literPlaceboAtacicept 25 mgAtacicept 75 mg
Change at Week 1-0.082 ± 0.0835-0.072 ± 0.0736-0.096 ± 0.0924
Change at Week 2-0.054 ± 0.1026-0.140 ± 0.1906-0.102 ± 0.1625
Change at Week 4-0.002 ± 0.1190-0.197 ± 0.2655-0.410 ± 0.1637
Change at Week 80.006 ± 0.1710-0.302 ± 0.3114-0.558 ± 0.1859
Change at Week 120.022 ± 0.0955-0.360 ± 0.3169-0.638 ± 0.2497
Change at Week 160.024 ± 0.1412-0.408 ± 0.3531-0.710 ± 0.2463
Change at Week 200.082 ± 0.2288-0.444 ± 0.3965-0.748 ± 0.2500
Change at Week 24-0.016 ± 0.1390-0.364 ± 0.3377-0.774 ± 0.2517
Change at Week 32-0.016 ± 0.1566-0.510 ± 0.4498-0.796 ± 0.2773
Change at Week 400.036 ± 0.1464-0.247 ± 0.1553-0.848 ± 0.2668
Change at Week 480.012 ± 0.1951-0.227 ± 0.1250-0.848 ± 0.2557
Change at Week 60-0.033 ± 0.0907-0.297 ± 0.2495-0.843 ± 0.2573
Change at Week 72-0.027 ± 0.0153-0.337 ± 0.2914-0.900 ± 0.3081
Change at Early Termination0.115 ± 0.0354-0.463 ± 0.1626-0.670 ± 0.1414
Change at PT FU Week 4-0.048 ± 0.1941-0.328 ± 0.1906-0.667 ± 0.2259
Change at PT FU Week 120.058 ± 0.2281-0.214 ± 0.1739-0.465 ± 0.2319
Change at PT FU Week 240.020 ± 0.1687-0.178 ± 0.1504-0.340 ± 0.1896
SecondaryChange From Baseline in Serum Galactose Deficient-IgA1 (Gd-IgA1) Levels

The change in serum Gd-IgA1 from baseline was reported.

Time frame:
Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72 and at PT FU Weeks 12 and 24
Reported as:
Mean · nanogram per milliliter (ng/mL)
Change From Baseline in Serum Galactose Deficient-IgA1 (Gd-IgA1) Levels
nanogram per milliliter (ng/mL)PlaceboAtacicept 25 mgAtacicept 75 mg
Change at Week 4-1438 ± 598.2-620 ± 1580.4-2288 ± 730.5
Change at Week 12-380 ± 1505.0-1672 ± 1459.2-2778 ± 1345.8
Change at Week 24160 ± 848.8-1912 ± 1835.0-3660 ± 1940.9
Change at Week 481140 ± 4339.5-423 ± 795.1-2938 ± 1756.9
Change at Week 72580 ± 2594.8-1327 ± 1181.4-3202 ± 1594.9
Change at Early Termination3520 ± 4638.6-2383 ± 2551.1-2680 ± 1258.7
Change at PT FU Week 121926 ± 3523.3-772 ± 2050.2-818 ± 1277.9
Change at PT FU Week 241673 ± 5072.9-1262 ± 2444.1-1090 ± 70.7
SecondaryChange From Baseline in Serum Complement C3 and C4 Levels

The change in serum component C3 and C4 from baseline were reported.

Time frame:
Baseline, Week 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Weeks 12 and 24
Reported as:
Mean · milligram per liter
Change From Baseline in Serum Complement C3 and C4 Levels
milligram per literPlaceboAtacicept 25 mgAtacicept 75 mg
Complement C3: Change at Week 12-60.0 ± 88.3280.0 ± 125.10122.0 ± 114.76
Complement C3: Change at Week 24-38.0 ± 100.85-6.0 ± 220.6470.0 ± 104.24
Complement C3: Change at Week 4882.0 ± 215.5763.3 ± 110.15162.5 ± 219.91
Complement C3: Change at Week 72-56.7 ± 127.4143.3 ± 212.21196.7 ± 196.55
Complement C3: Change at Early Termination-145.0 ± 190.92-60.0 ± 284.78180.0
Complement C3: Change at PT FU Week 12-12.0 ± 106.16-96.0 ± 196.67170.0 ± 390.00
Complement C3: Change at PT FU Week 24-85.0 ± 183.76-144.0 ± 93.97164.0 ± 205.45
Complement C4: Change at Week 12-26.8 ± 25.3513.4 ± 9.2433.8 ± 44.81
Complement C4: Change at Week 24-27.0 ± 32.268.8 ± 29.6634.3 ± 40.20
Complement C4: Change at Week 48-0.4 ± 20.7433.3 ± 18.9016.0 ± 27.89
Complement C4: Change at Week 72-43.0 ± 82.4612.0 ± 17.3549.7 ± 30.02
Complement C4: Change at Early Termination-22.0 ± 32.53-8.0 ± 38.57125.0
Complement C4: Change at PT FU Week 12-12.6 ± 32.00-4.2 ± 9.07-1.3 ± 44.52
Complement C4: Change at PT FU Week 24-37.0 ± 64.97-18.2 ± 30.3419.5 ± 18.30
SecondaryChange From Baseline in Immune Cell Subsets by Flow Cytometry Analysis

Change from baseline in immune cell subsets included total T cells, helper T cells, cytotoxic T cells, total B cells (assay with \[AW\] CD45 or assay without \[AWO\] CD45), mature naïve B cells, memory B cells, plasma cells, plasma blasts, and natural killer (NK) cells and were reported. Analysis was performed by flow cytometry analysis.

Time frame:
Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Week 24
Reported as:
Mean · cells per microliter
Change From Baseline in Immune Cell Subsets by Flow Cytometry Analysis
cells per microliterPlaceboAtacicept 25 mgAtacicept 75 mg
Cytotoxic T Cells: Change at Week 4—-22.5 ± 215.6746.7 ± 72.57
Cytotoxic T Cells: Change at Week 12713.0-114.075.0 ± 33.41
Cytotoxic T Cells: Change at Week 24101.5 ± 243.95-30.5 ± 125.1637.0 ± 39.60
Cytotoxic T Cells: Change at Week 489.0 ± 224.86—38.0 ± 42.43
Cytotoxic T Cells: Change at Week 72-60.0—-186.0 ± 289.91
Cytotoxic T Cells: Change at Early Termination282.0—45.0
Cytotoxic T Cells: Change at PT FU Week 24132.0——
Helper T Cells: Change at Week 4—59.0 ± 240.42114.7 ± 117.05
Helper T Cells: Change at Week 12124.0-51.0221.3 ± 85.33
Helper T Cells: Change at Week 24-79.0 ± 190.92134.0 ± 124.4585.0 ± 45.25
Helper T Cells: Change at Week 48-129.5 ± 338.70—72.5 ± 86.97
Helper T Cells: Change at Week 72-170.0—-312.5 ± 427.80
Helper T Cells: Change at Early Termination81.0—348.0
Helper T Cells: Change at PT FU Week 2490.0——
Mature naive B Cells: Change at Week 4—-76.5 ± 12.02-17.0 ± 78.31
Mature naive B Cells: Change at Week 12137.0-106.0-14.7 ± 94.07
Mature naive B Cells: Change at Week 241.0 ± 42.43-117.5 ± 51.62-87.5 ± 109.60
Mature naive B Cells: Change at Week 4821.5 ± 74.25—-91.0 ± 107.48
Mature naive B Cells: Change at Week 72-24.0—-32.0
Mature naive B Cells: Change at Early Termination36.0—-1.0
Mature naive B Cells: Change at PT FU Week 248.0——
Memory B Cells: Change at Week 4—8.014.5 ± 2.12
Memory B Cells: Change at Week 125.0—34.0 ± 0.00
Memory B Cells: Change at Week 24-1.5 ± 7.7813.05.5 ± 21.92
Memory B Cells: Change at Week 48-1.0 ± 4.24—5.0 ± 16.97
Memory B Cells: Change at Week 72-6.0—8.0
Memory B Cells: Change at Early Termination-3.0——
Memory B Cells: Change at PT FU Week 246.0——
NK Cells: Change at Week 4—19.0 ± 227.6988.3 ± 30.62
NK Cells: Change at Week 1243.0-105.074.0 ± 89.94
NK Cells: Change at Week 2444.5 ± 20.51-34.5 ± 112.4337.5 ± 58.69
NK Cells: Change at Week 4820.5 ± 16.26—39.0 ± 48.08
NK Cells: Change at Week 72130.0—104.0
NK Cells: Change at Early Termination54.0—12.0
NK Cells:Change at PT FU Week 2481.0——
Plasma Blasts: Change at Week 4—0.10-0.05 ± 0.071
Plasma Blasts: Change at Week 12-0.10—0.55 ± 0.212
Plasma Blasts: Change at Week 240.05 ± 0.071-0.300.10 ± 0.283
Plasma Blasts: Change at Week 481.40 ± 1.414—0.15 ± 0.212
Plasma Blasts: Change at Week 72-0.10—0.40
Plasma Blasts: Change at Early Termination0.80——
Plasma Blasts: Change at PT FU Week 243.40——
Plasma Cells: Change at Week 4—0.100.00 ± 0.141
Plasma Cells: Change at Week 12-0.10—0.15 ± 0.212
Plasma Cells: Change at Week 240.05 ± 0.071-0.100.00 ± 0.000
Plasma Cells: Change at Week 480.30 ± 0.283—0.00 ± 0.000
Plasma Cells: Change at Week 720.00—0.20
Plasma Cells: Change at Early Termination0.20——
Plasma Cells: Change at PT FU Week 240.10——
Total B cells (AW CD45): Change at Week 4—-50.0 ± 36.7737.3 ± 64.39
Total B cells (AW CD45): Change at Week 12154.0-105.0108.7 ± 88.90
Total B cells (AW CD45): Change at Week 24-0.5 ± 57.28-78.0 ± 131.52-32.5 ± 116.67
Total B cells (AWh CD45): Change at Week 4820.0 ± 91.92—-27.5 ± 115.26
Total B cells (AW CD45): Change at Week 72-31.0—2.0
Total B cells (AW CD45): Change at Early Termination43.0—71.0
Total B cells (AW CD45): Change at PT FU Week 2427.0——
Total B cells (AWO CD45): Change at Week 4—-33.0 ± 104.6541.0 ± 40.60
Total B cells (AWO CD45): Change at Week 1216.0-137.052.0 ± 65.09
Total B cells (AWO CD45): Change at Week 24-11.0 ± 53.74-96.5 ± 135.06-40.5 ± 88.39
Total B cells (AWO CD45): Change at Week 489.0 ± 113.14—-52.5 ± 81.32
Total B cells (AWO CD45): Change at Week 72-38.0—-78.0
Total B cells (AWO CD45): Change at Week Early Termination23.0—48.0
Total B cells (AWO CD45): Change at PT FU Week 24-36.0——
Total T Cells: Change at Week 4—40.0 ± 466.69169.0 ± 189.71
Total T Cells: Change at Week 12861.0-165.0314.7 ± 50.54
Total T Cells: Change at Week 2418.5 ± 419.31111.0 ± 260.22130.0 ± 2.83
Total T Cells: Change at Week 48-116.5 ± 564.98—113.5 ± 140.71
Total T Cells: Change at Week 72-227.0—-529.5 ± 767.21
Total T Cells: Change at Early Termination350.0—393.0
Total T Cells: Change at PT FU Week 24220.0——
SecondaryChange From Baseline in Urinary IgG, IgA, and IgM Levels

Urinary IgG, IgA and IgM levels to be measured by Immuno-Electrophoresis.

Time frame:
Baseline (Day1), Weeks 24, 48 and Early Termination (up to earlier than Week 72)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Positive Anti-Drug Antibody (ADA)

Percentage of participants with positive ADA were reported.

Time frame:
Baseline up to safety follow-up (96 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-Drug Antibody (ADA)
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mg
Percentage of Participants With Positive Anti-Drug Antibody (ADA)000
SecondaryPercentage of Participants With Clinical Significant Abnormalities in Laboratory Assessments

Laboratory investigation included hematology, biochemistry, urinalysis and Urine sediment analysis. Clinical significance was to be decided by the investigator.

Time frame:
Baseline up to safety follow-up (96 weeks)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Significant Abnormalities in Vital Signs

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, weight and height. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was to be decided by the investigator.

Time frame:
Baseline up to safety follow-up (96 weeks)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs)

12-lead ECG were recorded after the participants have rested for at least 15 minutes in supine position. Clinically significance was decided by the investigator. The number of participants with clinically significant abnormalities in 12-lead ECG were reported.

Time frame:
Baseline up to safety follow-up (96 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs)
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mg
Percentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs)000

Adverse events

Collected over Baseline up to safety follow up period (96 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/5 (0%)1/5 (20%)5/5 (100%)
Atacicept 25 mg0/6 (0%)3/6 (50%)6/6 (100%)
Atacicept 75 mg0/5 (0%)0/5 (0%)3/5 (60%)
Most frequent serious events
Most frequent serious events
EventPlaceboAtacicept 25 mgAtacicept 75 mg
Ovarian adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50/60/5
Acute kidney injuryRenal and urinary disorders0/51/60/5
Urinary bladder haemorrhageRenal and urinary disorders0/51/60/5
Gastroenteritis viralInfections and infestations0/51/60/5
Cervical spinal stenosisMusculoskeletal and connective tissue disorders0/51/60/5
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPlaceboAtacicept 25 mgAtacicept 75 mg
Injection site erythemaGeneral disorders0/54/61/5
Injection site bruisingGeneral disorders0/53/60/5
Injection site pruritusGeneral disorders0/53/60/5
Urinary tract infectionInfections and infestations0/53/60/5
Injection site reactionGeneral disorders0/51/62/5
DiarrhoeaGastrointestinal disorders2/50/60/5
Gastroenteritis viralInfections and infestations0/52/60/5
InfluenzaInfections and infestations0/52/60/5
PruritusSkin and subcutaneous tissue disorders0/52/60/5
Injection site inflammationGeneral disorders0/50/61/5

Baseline characteristics

The modified intent-to-treat (mITT) population included all randomized participants who had received at least 1 dose of the Investigational Medicinal Product (IMP).

Age, Continuous
Age, Continuous(years)PlaceboAtacicept 25 mgAtacicept 75 mgTotal
Mean46 ± 3.141 ± 16.943 ± 8.743 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtacicept 25 mgAtacicept 75 mgTotal
Female1528
Male4138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAtacicept 25 mgAtacicept 75 mgTotal
Hispanic or Latino0134
Not Hispanic or Latino55212
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAtacicept 25 mgAtacicept 75 mgTotal
American Indian or Alaska Native0000
Asian1113
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White45211
More than one race0000
Unknown or Not Reported0022
08

Study locations

18 sites
  • AKDHC Medical Research Services, LLC.
    Glendale, Arizona 85308, United States
  • California Institute of Renal Research - Chula Vista Location
    Chula Vista, California 91910, United States
  • Colorado Kidney Care PC - Dr. Marder
    Denver, Colorado 80218, United States
  • Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30909, United States
  • GA Nephrology Associates
    Lawrenceville, Georgia 30046, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent
    Columbus, Ohio 43210, United States
  • Northeast Clinical Research Center, LLC
    Bethlehem, Pennsylvania 18017, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • Nephrotex Research Group
    Dallas, Texas 75231, United States
  • Providence Sacred Heart Medical Center & Children's Hospital
    Spokane, Washington 99204, United States
  • Juntendo University Hospital - Dept of Nephrology/Hypertension
    Bunkyo-ku, 113-8431, Japan
  • University Hospitals of Leicester NHS Trust - ULTIMATE PARENT
    Leicester, LE5 4PW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website.

Data sharing details ↗ · www.emdgroup.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Feb 2020, 36 months.

Results were first posted in Feb 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2016
First posted
Jun 21, 2016
StartActual
Jan 31, 2017
Primary completionActual
Feb 7, 2020
CompletionActual
Feb 7, 2020
Results first posted
Feb 25, 2021
Last update
Feb 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02808429
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jan 31, 2017
Primary completion
Feb 7, 2020
Completion
Feb 7, 2020
Results posted
Feb 25, 2021
Last update
Feb 25, 2021

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion